Catalyst Pharmaceuticals Ownership | Who Owns Catalyst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Catalyst Pharmaceuticals Ownership Summary


Catalyst Pharmaceuticals is owned by 84.75% institutional investors, 5.57% insiders, and 9.68% retail investors. Blackrock is the largest institutional shareholder, holding 16.01% of CPRX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.75% of its assets in Catalyst Pharmaceuticals shares.

CPRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCatalyst Pharmaceuticals84.75%5.57%9.68%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock18.69M16.01%$289.58M
Blackrock funding, inc. /de18.77M15.35%$464.86M
Vanguard group8.43M6.88%$196.81M
State street6.86M5.61%$169.93M
American century companies4.14M3.38%$102.47M
Deerfield management company, l.p. (series c)3.94M3.22%$97.64M
Dimensional fund advisors lp3.43M2.80%$84.91M
Geode capital management2.97M2.43%$73.61M
Morgan stanley2.69M2.20%$66.54M
Renaissance2.35M1.92%$58.12M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Gables capital management424.58K4.45%$10.51M
Tanaka capital management114.42K4.06%$2.25M
Jw asset management388.39K3.95%$9.62M
Knott david m jr120.00K1.77%$2.97M
Globeflex capital l p450.58K1.69%$11.16M
Advisors preferred381.18K1.39%$9.44M
Qsv equity investors36.01K1.24%$840.47K
Mesirow institutional investment management742.29K1.19%$15.49M
Deerfield management company, l.p. (series c)3.94M1.15%$97.64M
Bridge city capital155.69K1.07%$3.85M

Top Buyers

HolderShares% AssetsChange
American century companies4.14M0.05%1.11M
Blackrock18.69M0.01%962.28K
Vanguard fiduciary trust802.63K0.01%802.63K
Susquehanna group, llp852.82K0.00%688.61K
Glenmede investment management, lp680.22K0.06%603.08K

Top Sellers

HolderShares% AssetsChange
Fundsmith llp844.89K0.16%-2.52M
Deerfield management company, l.p. (series c)3.94M1.15%-967.56K
Macquarie group---761.74K
Arrowstreet capital, limited partnership955.32K0.01%-661.89K
Invesco752.84K0.00%-540.64K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust802.63K0.01%802.63K$19.87M
Clark capital management group568.68K0.09%568.68K$14.08M
Imc-chicago563.67K0.01%563.67K$13.96B
William blair investment management479.04K0.04%479.04K$11.86M
Point72 asset management425.87K0.01%425.87K$10.54M

Sold Out

HolderChange
Global financial private client-1.00
Grey fox wealth advisors-1.00
Concord wealth partners-1.00
Turning point benefit group-2.00
Optima capital-5.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20263841.59%103,640,760-0.34%841.18%2005.26%119-6.30%
Dec 31, 2025317-13.39%84,692,615-18.03%690.97%157-11.30%105-21.64%
Sep 30, 2025351-3.57%103,180,9191.77%841.23%169-19.52%1295.74%
Jun 30, 2025354-3.54%101,094,7563.01%821.27%2043.55%118-2.48%
Mar 31, 20253616.80%97,419,101-0.16%801.19%193-4.46%11933.71%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF7.04M5.75%1.54K
Avantis US Small Cap Value ETF3.81M3.11%-
Vanguard Total Stock Mkt Idx Inv3.73M3.05%12.91K
Vanguard US Total Market Shares ETF3.55M2.91%3.78K
Smithson Investment Trust Ord3.36M2.75%-
iShares Russell 2000 ETF2.73M2.22%22.98K
State Street® SPDR® S&P® Biotech ETF2.53M2.07%-25.00K
First Trust NYSE Arca Biotech ETF1.89M1.59%-
Vanguard Institutional Extnd Mkt Idx Tr1.30M1.07%15.37K
SPDR® S&P Biotech ETF1.17M0.95%2.60K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 12, 2025Harper Molly-Sell$155.56K
Dec 12, 2025Harper Molly-Sell$106.16K
Dec 12, 2025Harper Molly-Sell$360.20K
Nov 26, 2025Del Carmen Jeffrey Chief Commercial OfficerSell$256.24K
Nov 12, 2025Elsbernd Brian Chief Compliance/Legal OfficerBuy$908.00K

Insider Transactions Trends


DateBuySell
2026 Q2--
2026 Q1--
2025 Q4-5
2025 Q3-6
2025 Q2-7

CPRX Ownership FAQ


Who Owns Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals shareholders are primarily institutional investors at 84.75%, followed by 5.57% insiders and 9.68% retail investors. The average institutional ownership in Catalyst Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Catalyst Pharmaceuticals exceeds.

Who owns the most shares of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals’s largest shareholders are Blackrock (18.69M shares, 16.01%), Blackrock funding, inc. /de (18.77M shares, 15.35%), and Vanguard group (8.43M shares, 6.88%). Together, they hold 38.24% of Catalyst Pharmaceuticals’s total shares outstanding.

Does Blackrock own Catalyst Pharmaceuticals?

Yes, BlackRock owns 16.01% of Catalyst Pharmaceuticals, totaling 18.69M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 289.58M$. In the last quarter, BlackRock increased its holdings by 962.28K shares, a 5.43% change.

Who is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Gables capital management is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.45% of its assets in 424.58K Catalyst Pharmaceuticals shares, valued at 10.51M$.

Who is the top mutual fund holder of Catalyst Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Catalyst Pharmaceuticals shares, with 5.75% of its total shares outstanding invested in 7.04M Catalyst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools